Characterization of platelet-related genes and constructing signature combined with immune-related genes for predicting outcomes and immunotherapy response in lung squamous cell carcinoma

Aging (Albany NY). 2023 Jul 20;15(14):6969-6992. doi: 10.18632/aging.204886. Epub 2023 Jul 20.

Abstract

Lung squamous cell carcinoma (LUSC) is a highly malignant subtype of non-small cell lung cancer with poor prognosis. Platelets are known to play a critical role in cancer development and progression, and recent studies suggest that they can also regulate immune response in tumors. However, the relationship between platelet-related genes (PRGs) and LUSC prognosis and tumor microenvironments remains unclear. In this study, we used multiple bioinformatics algorithms to identify 25 dysregulated PRGs that were significantly associated with LUSC prognosis. We found that PRGs were involved in multiple biological processes, particularly in the tumor microenvironment, and that platelet-related scores (PRS) were a risk factor. Additionally, we established a 6-gene prognostic signature combining PRGs and immune-related genes that accurately predicted outcomes and immunotherapy efficacy in LUSC patients. Our study provides a comprehensive analysis of the biological functions and potential therapeutic targets of PRGs in LUSC, which may inform the development of new treatments for this disease.

Keywords: immunity; lung squamous cell carcinoma; platelet-related genes; prognosis; tumor microenvironments.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Platelets
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / therapy
  • Carcinoma, Squamous Cell* / genetics
  • Carcinoma, Squamous Cell* / therapy
  • Humans
  • Immunotherapy
  • Lung
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / therapy
  • Prognosis
  • Tumor Microenvironment / genetics